What are the recent trends in market size and growth for the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market size has grown exponentially in recent years. It will grow from $10.36 billion in 2024 to $13.32 billion in 2025 at a compound annual growth rate (CAGR) of 28.5%. The growth in the historic period can be attributed to rising prevalence of transthyretin amyloid cardiomyopathy, increasing prevalence of transthyretin amyloidosis among geriatric patients, increasing awareness among healthcare professionals and patients, growth in awareness and improvement of healthcare services.
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market size is expected to see exponential growth in the next few years. It will grow to $35.93 billion in 2029 at a compound annual growth rate (CAGR) of 28.2%. The growth in the forecast period can be attributed to increasing prevalence of transthyretin amyloidosis, rise in diagnosis of neuropathic disorders, rising demographic of aging population, increase in demand for specific drugs for treating symptoms of the rare disorder, increasing demand for healthcare. Major trends in the forecast period include new diagnostic technologies, development of innovative techniques for the therapy management, innovative and targeted treatments for transthyretin amyloidosis, advancements in diagnostics techniques, cardiac MRI techniques.
Get Your Free Sample of The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp
How have varous drivers impacted the growth of the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?
The rising prevalence of chronic diseases is expected to propel the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market going forward. Chronic diseases are long-lasting conditions that progress slowly and persist for a year or more, often requiring continuous medical care. The rising prevalence of chronic diseases is attributed to factors such as aging populations, sedentary lifestyles, unhealthy diets, increasing obesity rates, and exposure to environmental pollutants. Transthyretin amyloid cardiomyopathy treatment helps by stabilizing transthyretin, reducing amyloid buildup, improving heart function, and alleviating symptoms to better manage related chronic conditions. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year. Globally, there were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, the rising prevalence of chronic diseases is driving the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
What are the primary segments of the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented –
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-global-market-report
Which firms are leading the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?
Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG
How will industry trends affect the trajectory of the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?
Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are focusing on developing innovative treatments for ATTR-CM, such as oral prescription medication to target and stabilize transthyretin (TTR) proteins or reduce amyloid fibril buildup in the heart. Oral prescription medication refers to drugs prescribed by a healthcare provider that are taken by mouth, typically in the form of tablets, capsules, or liquid solutions. For instance, in November 2024, BridgeBio Pharma Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration for Attruby (acoramidis) for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This stabilizes the TTR protein, reducing heart-related deaths and hospitalizations. Clinical trials have shown that it is well-tolerated and provides rapid benefits by targeting the root cause of the disease.
Which geographic trends are shaping the transthyretin amyloid cardiomyopathy (attr-cm) treatment market, and which region has the highest market share?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report 2025 Offer?
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment refers to medical therapies and interventions aimed at managing ATTR-CM, a progressive and life-threatening disease caused by the buildup of misfolded transthyretin (TTR) proteins in the heart, leading to restrictive cardiomyopathy and heart failure.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
